Vitiligo-Pipeline Review, H1 2017

Vitiligo-Pipeline Review, H1 2017


  • Products Id :- GMDHC9234IDB
  • |
  • Pages: 81
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Vitiligo-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo-Pipeline Review, H1 2017, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).

The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vitiligo-Overview

Vitiligo-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vitiligo-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vitiligo-Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Biocon Ltd

Bristol-Myers Squibb Company

Celgene Corp

Clinuvel Pharmaceuticals Ltd

Incyte Corp

Vitiligo-Drug Profiles

abatacept-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afamelanotide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vitiligo-Dormant Projects

Vitiligo-Product Development Milestones

Featured News & Press Releases

Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study

Dec 03, 2015: Update on North American vitiligo program for SCENESSE

May 05, 2015: Clinuvel announces innovative melanocortin for new indications

Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference

Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology

May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore

Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology

Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore

Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients

Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference

Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo

Oct 16, 2012: Observations from Clinuvels US vitiligo study published

Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the

Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Vitiligo, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Vitiligo, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Vitiligo-Pipeline by Aclaris Therapeutics Inc, H1 2017

Vitiligo-Pipeline by Biocon Ltd, H1 2017

Vitiligo-Pipeline by Bristol-Myers Squibb Company, H1 2017

Vitiligo-Pipeline by Celgene Corp, H1 2017

Vitiligo-Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2017

Vitiligo-Pipeline by Incyte Corp, H1 2017

Vitiligo-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aclaris Therapeutics Inc, Biocon Ltd, Bristol-Myers Squibb Company, Celgene Corp, Clinuvel Pharmaceuticals Ltd, Incyte Corp

select a license

Single User License
USD 2000 INR 129880
Site License
USD 4000 INR 259760
Corporate User License
USD 6000 INR 389640

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com